Appointment of Steven Bloom as Chief Business Officer brings over 35 years of life sciences industry experience, which could enhance Werewolf's strategic development and business initiatives. Bloom's ...
Research and development expenses: Research and development expenses were $6.9 million for the fourth quarter of 2025, compared to $15.7 million for the same period in 2024. Research and development ...
WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of ...
"Steve brings deep experience in strategic transactions to Werewolf at this critical time," said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. "Werewolf is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results